Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome.

Yang He, Weijin Fang, Zuojun Li, Chunjiang Wang

Abstract read

In one paragraph

Article in Investigational new drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.3field-weighted citation impact, top 40% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yang HeDepartment of Pharmacy, The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China.

Weijin FangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.

Zuojun LiDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.

Chunjiang WangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. wongcj@csu.edu.cn.ORCID http://orcid.org/0000-0001-6067-8305

Central South University · CNFirst Affiliated Hospital of Hunan University of Traditional Chinese Medicine · CN

Funding

School Science Foundation of Hunan University of Chinese Medicine 2021XJJJ040

6 · The paper itself

Abstract

Knowledge of dasatinib-induced nephrotic syndrome is largely based on case reports. The clinical features of dasatinib-induced nephrotic syndrome are unknown. We collected case reports of 25 patients with nephrotic syndrome and analyzed their clinical characteristics. Overall, the onset of nephrotic syndrome ranged from 10 days to 5 years after dasatinib administration. Nine patients (36.0%) had clinical symptoms, mainly periorbital edema and lower-extremity edema. Serum albumin ranged from 1.2 g/dL to 3.7 g/dL in 10 patients (38.5%). The 24-h urine protein values ranged from 3.54 g/day to 118 g/day. Kidney biopsy of 13 patients (52.0%) mainly showed focal foot process effacement, mesangial hyperplasia, endothelial cell damage and focal segmental glomerulosclerosis. Proteinuria resolved or recovered after dasatinib discontinuation or dose reduction or switching to other tyrosine kinase inhibitors (TKIs).

Indexed as

Glomerulosclerosis, Focal SegmentalNephrotic SyndromeDasatinibHumansProteinuriaSerum AlbuminDasatinibSerum AlbuminAdverse eventDasatinibNephrotic syndromeProteinuriaRenal disease

Identifiers

PMID35867286

DOI10.1007/s10637-022-01288-6

OpenAlexW4286447645

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.